Biblio

Author Title Type [ Year(Desc)]
Filters: Author is DeZern, Amy E  [Clear All Filters]
2014
Gondek LP, DeZern AE. I Walk the Line: How to Tell MDS From Other Bone Marrow Failure Conditions. Curr Hematol Malig Rep. 2014.
2018
DeZern AE, Jones RJ, Brodsky RA. Eculizumab Bridging Before Bone Marrow Transplant for Marrow Failure Disorders is Safe and Does Not Limit Engraftment. Biol Blood Marrow Transplant. 2018.
Ball B, Komrokji RS, Ades L, Sekeres MA, DeZern AE, Pleyer L, Vey N, Almeida A, Germing U, Cluzeau T, et al. Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. Blood Adv. 2018;2(16):2063-2071.
2019
Imus PH, Blackford AL, Bettinotti M, Luznik L, Fuchs EJ, Huff CAnn, Gladstone DE, Ambinder RF, Borrello IM, Fuchs RJ, et al. Severe cytokine release syndrome after haploidentical peripheral blood transplantation. Biol Blood Marrow Transplant. 2019.
2020
DeZern AE, Zahurak ML, Symons HJ, Cooke KR, Rosner GL, Gladstone DE, Huff CAnn, Swinnen LJ, Imus P, Borrello I, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020;4(8):1770-1779.
Lally K, Kruse RL, Smetana H, Davis R, Roots A, Marshall C, Ness PM, DeZern AE, Gladstone DE, Brennan DC, et al. Isohemagglutinin titering performed on an automated solid-phase and hemagglutinin-based analyzer is comparable to results obtained by manual gel testing. Transfusion. 2020.
DeZern AE, Gondek LP. Stem cell donors should be screened for CHIP. Blood Adv. 2020;4(4):784-788.
2021
Rappazzo KC, Zahurak M, Bettinotti M, Ali SAbbas, Ambinder AJ, Bolaños-Meade J, Borrello I, DeZern AE, Gladstone D, Gocke C, et al. Nonmyeloablative, HLA-mismatched unrelated peripheral blood transplantation with high-dose posttransplantation cyclophosphamide. Transplant Cell Ther. 2021.
Tschernia NP, Kumar V, Moore DT, Vincent BG, Coombs CC, Van Deventer H, Foster MC, DeZern AE, Luznik L, Riches ML, et al. Safety and efficacy of pembrolizumab prior to allogeneic stem cell transplant in Acute Myeloid Leukemia. Transplant Cell Ther. 2021.
2022
DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, et al. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines. Transplant Cell Ther. 2022.
2023
Stahl M, Bewersdorf JPhilipp, Xie Z, Porta MGiovanni D, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, et al. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev. 2023:101128.
Bewersdorf JPhilipp, Xie Z, Bejar R, Borate U, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, et al. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1 International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Rev. 2023:101072.
Belbachir S, Abraham A, Sharma A, Prockop S, DeZern AE, Bonfim C, Bidgoli A, Li J, Ruggeri A, Bertaina A, et al. Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond. Cytotherapy. 2023.
Di Nardo M, MacLaren G, Schellongowski P, Azoulay E, DeZern AE, Gutierrez C, Antonelli M, Antonini MV, Beutel G, Combes A, et al. Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement. Lancet Respir Med. 2023.
Randall MP, DeZern AE. The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances. Cancer J. 2023;29(3):152-159.
Dong J, Buradagunta CStaffi, Zhang T, Spellman S, Bolon Y-T, DeZern AE, Gadalla SM, H Deeg J, Nazha A, Cutler C, et al. Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation. J Hematol Oncol. 2023;16(1):21.
Zhang T, Auer P, Dong J, Cutler C, DeZern AE, Gadalla SM, H Deeg J, Nazha A, Carlson K-S, Spellman S, et al. Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study. J Hematol Oncol. 2023;16(1):37.